Cargando…
Androgenetic alopecia: An update
Androgenetic alopecia (AGA) is the most common nonscarring alopecia and is characterised by distinct gradual patterned hair loss. AGA is mediated by genetic predisposition and excessive follicular sensitivity to androgens, mainly in males, leading to the progressive conversion of scalp terminal hair...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562178/ https://www.ncbi.nlm.nih.gov/pubmed/37823040 http://dx.doi.org/10.1016/j.jdin.2023.07.005 |
_version_ | 1785118068742029312 |
---|---|
author | Ntshingila, Sincengile Oputu, Ogheneochuko Arowolo, Afolake T. Khumalo, Nonhlanhla P. |
author_facet | Ntshingila, Sincengile Oputu, Ogheneochuko Arowolo, Afolake T. Khumalo, Nonhlanhla P. |
author_sort | Ntshingila, Sincengile |
collection | PubMed |
description | Androgenetic alopecia (AGA) is the most common nonscarring alopecia and is characterised by distinct gradual patterned hair loss. AGA is mediated by genetic predisposition and excessive follicular sensitivity to androgens, mainly in males, leading to the progressive conversion of scalp terminal hair into vellus hair. Although highly prevalent, it is not fatal but may have a severe psychosocial impact, especially on females and younger males. Significant advances have been made in understanding AGA's epidemiology and pathophysiology, but only 2 drugs remain approved by the FDA - finasteride and minoxidil. Prolonged use of these drugs, is a prerequisite for enhanced treatment response. However, this leads to poor medication adherence and adverse effects from extended use eg, the “postfinasteride syndrome” which persists beyond stopping the drug. Hence, there is a need for research on more effective alternative treatments for AGA, with fewer side effects. This paper reviewed recent advances in AGA pathophysiology and its treatment options. The recently characterized structure of type 2, 5-alpha reductase holds significance in comprehending present and prospective treatments of AGA. |
format | Online Article Text |
id | pubmed-10562178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105621782023-10-11 Androgenetic alopecia: An update Ntshingila, Sincengile Oputu, Ogheneochuko Arowolo, Afolake T. Khumalo, Nonhlanhla P. JAAD Int Review Androgenetic alopecia (AGA) is the most common nonscarring alopecia and is characterised by distinct gradual patterned hair loss. AGA is mediated by genetic predisposition and excessive follicular sensitivity to androgens, mainly in males, leading to the progressive conversion of scalp terminal hair into vellus hair. Although highly prevalent, it is not fatal but may have a severe psychosocial impact, especially on females and younger males. Significant advances have been made in understanding AGA's epidemiology and pathophysiology, but only 2 drugs remain approved by the FDA - finasteride and minoxidil. Prolonged use of these drugs, is a prerequisite for enhanced treatment response. However, this leads to poor medication adherence and adverse effects from extended use eg, the “postfinasteride syndrome” which persists beyond stopping the drug. Hence, there is a need for research on more effective alternative treatments for AGA, with fewer side effects. This paper reviewed recent advances in AGA pathophysiology and its treatment options. The recently characterized structure of type 2, 5-alpha reductase holds significance in comprehending present and prospective treatments of AGA. Elsevier 2023-07-22 /pmc/articles/PMC10562178/ /pubmed/37823040 http://dx.doi.org/10.1016/j.jdin.2023.07.005 Text en © 2023 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Ntshingila, Sincengile Oputu, Ogheneochuko Arowolo, Afolake T. Khumalo, Nonhlanhla P. Androgenetic alopecia: An update |
title | Androgenetic alopecia: An update |
title_full | Androgenetic alopecia: An update |
title_fullStr | Androgenetic alopecia: An update |
title_full_unstemmed | Androgenetic alopecia: An update |
title_short | Androgenetic alopecia: An update |
title_sort | androgenetic alopecia: an update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562178/ https://www.ncbi.nlm.nih.gov/pubmed/37823040 http://dx.doi.org/10.1016/j.jdin.2023.07.005 |
work_keys_str_mv | AT ntshingilasincengile androgeneticalopeciaanupdate AT oputuogheneochuko androgeneticalopeciaanupdate AT arowoloafolaket androgeneticalopeciaanupdate AT khumalononhlanhlap androgeneticalopeciaanupdate |